Navigation Links
Antipodean Pharmaceuticals Announces FDA Acceptance of IND for MitoQ(R)

SAN FRANCISCO, June 3 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's Investigational New Drug (IND) application for its lead compound, MitoQ(R). With the IND acceptance, the Company will involve U.S. clinical centers in the development of MitoQ for the treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD).

"We look forward to working with FDA to further explore MitoQ's potential by conducting further trials in the United States," said Ken Taylor, Ph.D., Chief Executive Officer of Antipodean Pharmaceuticals. "The Company is actively seeking a pharmaceutical partner with whom to work to achieve this goal."

In April 2008, the Company announced positive results of a clinical study of MitoQ in patients with Hepatitis C virus (HCV) who had failed standard antiviral treatment. The data from this Phase 2 trial were presented at the European Association for the Study of Liver (EASL) conference. Results showed a significant reduction in elevated alanine aminotransferase (ALT) levels as compared to placebo. The ALT decrease from baseline was 26.4% (p<0.002) for patients in the 40mg dose group. This suggests that MitoQ can reduce necroinflammation and may halt disease progression to fibrosis or cirrhosis. The drug was well tolerated, with no significant safety issues.

About MitoQ(R)

MitoQ is a mitochondria-targeted antioxidant that selectively blocks mitochondrial oxidative damage and prevents liver cell apoptosis. MitoQ is based on a novel technology, targeted lipophilic cations that transport and concentrate antioxidants into the mitochondria-organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. MitoQ can reduce the hepatic oxidative damage that is induced by viral infection and that is also involved in the progression of Non-alcoholic Fatty Liver Disease (NAFLD) through to Non-alcoholic Steatohepatitis (NASH), leading to fibrosis or cirrhosis.

About Non-alcoholic Fatty Liver Disease (NAFLD)

Symptoms of NAFLD include fat deposits, inflammation of the liver, and elevated liver enzymes -- ALT and AST. As with Hepatitis C, oxidative stress is involved in NAFLD disease progression to fibrosis and cirrhosis. NAFLD affects approximately 20% of the world's population and the incidence is growing rapidly as obesity rates rise. There are currently no satisfactory treatment options.

About Antipodean

Antipodean is a clinical-stage pharmaceutical company developing targeted molecules that prevent oxidative damage to endothelial, epithelial and liver cells leading to apoptosis and fibrosis. The Company is developing a mitochondria-targeted antioxidant, MitoQ (mitoquinone mesylate), for the treatment of hepatic inflammatory disorders caused by oxidative stress such as NAFLD and NASH. The Company's business plan is to develop drugs to the point of proof of principle and then partner further development. Antipodean has research collaborations with pre-clinical and clinical investigators in Cambridge, UK, Auckland, New Zealand, and several centers in the US to identify and develop lead compounds through to clinical proof-of-principle. Currently the Company's lead compounds target liver and skin diseases. Antipodean is located in San Francisco, California. Further information is available at

SOURCE Antipodean Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
2. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
3. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
6. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
7. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
8. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
9. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
Post Your Comments:
(Date:11/29/2015)... ... ... Effective immediately, every single IguanaMed scrub style will be available at Target via ... “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for a limited ... price. , IguanaMed’s mission is to outfit every healer around the world ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again ... choose from, the possibilities are endless. Users have full control over angle of view, ... masking effects, users are sure to get heads to turn. , ProPanel: Pulse offers ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 6th ... the University of British Columbia suggested that laws requiring bicyclists to wear helmets may ... part of the reason for the controversial conclusion is that, while helmets have certainly ...
(Date:11/27/2015)... , ... November 27, 2015 , ... A team of ... ways to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: